NCCN 2021 Virtual Congress: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium Friday, February 12, 2021 12:25 PM - 1:10 PM EST

# Surgical and Radiation Treatment Updates to **Management of Breast Cancer**, Including SABCS Updates

### Doreen M. Agnese, MD

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

### Meena S. Moran, MD

Yale Cancer Center/Smilow Cancer Hospital

National Comprehensive NCCN Cancer Network®

NCCN.org – For Clinicians | NCCN.org/patients – For Patients

NCCN 2021 Virtual Congress: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium

# Surgical Treatment Updates to Management of Breast Cancer, Including SABCS Updates

### Doreen M. Agnese, MD

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute



NCCN.org – For Clinicians NCCN.org/patients – For Patients

# Background

- Optimal breast cancer care requires a multidisciplinary approach
  - Surgery
  - Radiation therapy
  - Systemic therapy (adjuvant or neoadjuvant)
  - Supportive care
- For those with early stage cancer, surgery is often the first therapy
  - Care of the primary tumor with breast conservation or mastectomy
  - Axillary staging
- Locoregional treatment strategies have evolved over the years to maximize effectiveness and minimize morbidity


© National Comprehensive Cancer Network, Inc. 2021, All Rights Reserved. No part of this publication may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from NCCN®.

The James

# Axillary Staging, clinically node negative

- Key prognostic predictor with significant impact on treatment planning
- Historically, axillary node dissection was required for staging of the axilla
  - Significant morbidity, including lymphedema
- Sentinel lymph node biopsy
  - Allowed accurate staging and avoidance of completion nodal dissection when sentinel node was negative
  - When first introduced, was followed by completion nodal dissection in those who had positive SLN
  - More recent studies have demonstrated node positive populations where axillary node dissection is not required

The James
THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER



# Omission of SLN

VOLUME 24 - NUMBER 3 - JANUARY 20 2006

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93

International Breast Cancer Study Group

#### ABSTRACT

#### Study Group. Appendix lists the names and affiliations of the writing committee, and participants and authors of Trial 10-83. Submitted February 14, 2005; accepted

From the International Breast Cancer

June 13, 2005.

Supported in part by the Swiss Group for Clinical Concern Research, Frontier Science and Technology Research Foundation, The Cancer Council Australia, Australian New Zealand Breast Cancer Trails Group National Health Medical Besearch Council, National Cancer Institute Tigrant No. Cancer Association of Scark Atrica, and Foundation of Clinical Research of Eastem Skittsränd.

Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Address reprint requests to Carl-Magnus Rudenstam, MD, West Swedish Breast Cancer Study Group, Sahlgrenka University Hospital/Molindal, Göteborgsvägen 21, 423 GM/Mored, Göteborgsvägen Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information but is associated with undesirable morbidity. We therefore investigated whether avoiding axillary surgery in older women would result in improved quality of life (QL) with similar disease-free survival (DFS) and overall survival (OS).

#### Patients and Methods

Between 1993 and 2002, women  $\ge 60$  years old with clinically node-negative operable breast cancer in whom adjuvant tamoxifen was considered indicated regardless of pathologic nodal status were randomly assigned to primary surgery plus axillary clearance (Sx + Ax) followed by tamoxifen (Tam) versus Sx without Ax followed by Tam for 5 consecutive years. The primary end point was QL reported by the patient and by physician assessment.

#### Results

À total of 473 patients (234 to Sx + Ax, 239 to Sx) were randomly assigned. The median age was 74 years; 80% had estrogen receptor-positive disease. In both the patients' subjective assessment of their OL and the physicians' perception of the patients' OL, the largest adverse OL effects of Ax were observed from baseline to the first postoperative assessment, but the differences tended to disappear in 6 to 12 months. At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (Feyaer DFS, 67% v 66%), hazard ratio (HR) Sx + AvSx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + AvSx, 1.05; 95% CI, 0.76 to 1.46; P = .77).


J Clin Oncol 24:337-344. @ 2006 by American Society of Clinical Oncology


- RCT of women  $\geq$  60
  - Clinically node negative
  - Adjuvant tamoxifen
- 473 patients randomly assigned to surgery and tamoxifen with and without axillary clearance



WEXNER MEDICAL CENTER

THE OHIO STATE UNIVERSITY








# Choosing Wisely Campaign


- Society of Surgical Oncology statement (released July 2016, updated June 2019)
- Don't routinely use sentinel node biopsy in clinically node negative women ≥70 years of age with early stage hormone receptor positive, HER2 negative invasive breast cancer.

	The James
n	THE OHIO STATE UNIVERSITY
	WEXNER MEDICAL CENTER











AMAROS Trial	
<ul> <li>Multicenter prospective randomized trial</li> <li>4823 patients with T1-2 tumors and clinically negative nodes warandomized to either axillary node dissection or radiation therasetting of a positive sentinel node</li> <li>82% had lumpectomy, 17-18% had mastectomy</li> </ul>	
Donker The Lancet Oncology 2014; 15 (12): 1303-1310	The James THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER







# Clinically negative axilla with abnormal ultrasound

- Some centers perform axillary ultrasound even when no nodes are clinically palpable
- If biopsy performed and positive, patient may still meet Z11 criteria and can still be offered SLN
- Efforts should be made to clip the sampled node at the time of biopsy and remove at the time of SLN to assure accuracy of axillary staging

© National Comprehensive Cancer Network, Inc. 2021, All Rights Reserved. No part of this publication may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from NCCN®.

The James






# Axillary assessment after neoadjuvant therapy


- Historically, axillary node dissection was required for all patients with positive nodes prior to neoadjuvant chemotherapy regardless of response
- SLN after neoadjuvant therapy
  - Identification rate of about 89%
  - False negative rate >10%
  - Negative predictive value of 56-87%

© National Comprehensive Cancer Network, Inc. 2021, All Rights Reserved. No part of this publication may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from NCCN®.

The James

Targeted A	xillary Dissection			
	VOLUME 34 · NUMBER 10 · APRIL 1, 2016 JOURNAL OF CLINICAL ONCOLOGY	ORIGINAL REPORT		
	Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection Abigail S. Caudle, Wei T. Yang, Savitri Krishnamurthy, Elizabeth A. Mittendorf, Dalliah M. Black, Michael Z. Gilcrease, Isabelle Bedrosian, Brian P. Hobbs, Sarah M. DeSnyder, Rosa F. Hwang, Beatriz E. Adrada, Simmon F. Shaitelman, Mariana Chavez-MacGregor, Benjamin D. Smith, Rosalind P. Candelaria, Gildy V. Babiera, Basak E. Dogan, Lumarie Santiago, Kelly K. Hunt, and Henry M. Kuerer			
<ul> <li>Prospective study of patients with biopsy proven positive nodes with clip placed at biopsy</li> </ul>				
After neoadjuvant therapy, patients had SLN and removal of the clipped node with iodine-125 seed localization				
		The James		





# **RISAS Trial-presented at SABCS 2020**

- Radioactive Iodine Seed localization in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
- Prospective multicenter trial in which patients underwent RISAS procedure followed by axillary node dissection
  - 223 patients had successful identification of at least one lymph node
  - 79 had pathologic complete response
  - 144 had residual nodal disease
  - 5 patients had false negative RISAS procedure (FNR 3.4%, NPV 93.6%)
    - Of the 5 false negatives, 4/5 occurred within the 1<sup>st</sup> 10 procedures performed at the institution

The James

THE OHIO STATE UNIVERSITY

RISAS trial- Abstract Number: GS1-10; SABCS 2020

# Summary

- Routine SLN should can be omitted in select patients ≥ 70 with early stage HR+, Her-2 negative breast cancer
- SLN is recommended for axillary staging in clinically node negative patients
- Completion nodal dissection can be avoided in patients who meet Z11 criteria
- There is growing evidence that modifications of SLN with addition of TAD may allow de-escalation of axillary surgery after neoadjuvant chemotherapy

	The James
	THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
28	



NCCN 2021 Virtual Congress: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium

# **Radiation Treatment Updates to Management of Breast Cancer, Including SABCS Updates**

# Meena S. Moran, MD

Yale Cancer Center/Smilow Cancer Hospital



NCCN.org – For Clinicians | NCCN.org/patients – For Patients


# Learning Objectives

- Develop an evidence-based approach for the management of the axilla in patients with early stage breast cancer
- Individualize radiation therapy recommendations based on patient and tumor characteristics
- Discuss new and emerging data in the management of patients with early-stage breast cancer and integrate key findings into clinical practice


# Definitions of Margins after BCT in 2014: Variations by Current Consensus Groups

Consensus Group	Recommended Negative Margin Width
National Comprehensive Cancer Network (NCCN)	>1 mm
European Society for Medical Oncology (ESMO)	<u>&gt;</u> 2 mm
New Zealand Guidelines Group (NZGG)	<u>&gt;</u> 2 mm
German Cancer Society	<u>&gt;</u> 1 mm

JOURNAL OF CLINICAL ONCOLOGY	SPECIAL ARTICLE
Society of Surgical Oncology–Am Radiation Oncology Consensus G Breast-Conserving Surgery With in Stages I and II Invasive Breast G	Guideline on Margins for Whole-Breast Irradiation
	Moran MS et al. 2014
*Guidelines simultaneously published in JCO,	Int J. Radiat Bio Phy/PRO, & Annals Surg Onc



© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN<sup>®</sup>. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.



JOURNAL OF CLINICAL ONCOLOGY	SPECIAL ARTICLE	
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer		
Moran MS et al. 2014		
JOURNAL OF CLINICAL ONCOLOGY	SPECIAL ARTICLE	
Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ Morrow M et al. 2016		
*Both guidelines simultaneously published in JCO, Int J. Radiat Bio Phy/PRO, & Annals Surg Onc		

National Comprehensive Cancer

Network\*

NCCN

### NCCN Guidelines Version 3.2017 Invasive Breast Cancer

### MARGIN STATUS RECOMMENDATIONS FOR BOTH DCIS AND INVASIVE BREAST CANCER

Margins should be evaluated on all surgical specimens from breast-conserving surgery (BCS). Requirements for optimal margin breast-conserving surgery (BCS). Requirements for optimal margin of the distance, orientation, and type of tumor (invasive or DCIS) in relation to the closest margin status Complete resection should be documented by analysis of margins and specimen radiography. Post-excision mammography could also be performed whenever uncertainty about adequacy of excision remains. The NCCN panel accepts the definitions of negative margins after breast conservation therapy from the 2014 SSO/ASTRO Margins Guideline <sup>1</sup> for Stage JIII Invasive cancers after BCS, a positive margin is defined as "ink on tumor" (any invasive cancer or DCIS cells on ink). These patients generally require further surgery—either a re-excision to achieve a negative allow for BCS to achieve "no ink on tumor," this can be done with resection specimen or re-excision of the entire original excision cavity. There may be select patients with stage III invasive cancers who may be eligible for BCS. For these patients, the margins status would be accessed with similar definitions.		<ul> <li>Invasive Breast Cancer</li> <li>For invasive breast cancers that have a component of DCIS, regardless of the extent of DCIS, the negative margin definition of "no ink on tumor" should be based on the invasive margin guideline. In this setting, "no ink on tumor" is recommended for either DCIS or invasive cancer cells, primarily because the natural history, treatment, and outcomes of these lesions is more similar to invasive cancer the applied in specific cases for which following discussion with the patient, re-excision may be prudent.</li> <li>These margin recommendations cannot be applied directly to patients undergoing APBI,<sup>2</sup> where data regarding local recurrence is more limited. Furthermore, individualized clinical judgment should be utilized on a case-by-case basis, using postoperative mammography to identify residual calcifications and clinical-pathologic factors such as quantitative extent of disease near margin, presence of extensive intraductal component (EIC), young age, or multiple close margins to assist in identifying patients who may have an increased risk of IBTR and therefore may be selected to benefit from re-excision.</li> <li>For patients with invasive breast cancer, after BCS if margin is microscopically focally positive, in the absence of an (EIC),<sup>3</sup> the use of a higher radiation boost dose to the tumor bed should be considered. A boost to the tumor bed is recommended in patients at higher risk for recurrence. Typical doses are 10–16 Gy at 2 Gy/fx.</li> </ul>	
<sup>1</sup> Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American So conserving surgery with whole-breast irradiation in stages I and II invasive breast ca <sup>2</sup> Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Socie Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation i Note: All recommendations are category 24 unless otherwise indicated. Clinical Thats: NCCM believes that the best management of any patient with cancer is in a clinical Veiso 3 2017, 11/1017 National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCON Guidence and this Illustation	nceř. J Clin Oncol 2014 May 10;32(14);1507-15. tý for Radiation Oncology-American Society of Clinical Oncology Consensus n Ductal Carcinoma In Situ. J Clin Oncol 2016;34:4040-4046. trial. Participation in clinical trials is especially encouraged.	<sup>1</sup> Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline o conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol (2014 May 10.32(14):1507-15. "Aforrow M. Van Zee KJ. Solin L. et al. Society of Surgical Concology-American Society for Radiation Oncology-American Society of Caladian Oncology-American Society of Radiation Oncology-American Society of Caladian Oncology-American Society of Caladian Oncology-American Society of Caladian Oncology-American Society for Radiation Oncology-American Society of Caladian Oncology-American Society for Radiation Oncology-American Society of Caladian Oncol 2016;8:4:4040-404 <sup>2</sup> GIC is defined as in infiniting ductal cancer where greater than 25% of the tumor volume is DCIS and DCIS extends beyond the invasive cano normal breast parenchyma. Note: All recommodations are category 24 unless otherwise indicated. Unless 1307, 10/071 Materia Carpheres Carphanes, pp. 2017,4:19to mend Tel/COS/Adming*Aetro Is in a clinical trial, the understage and participation on clinical trials is especially encouraged.	blogy Consensus

Which Guideline to Use?				
DCIS guidelin	e	DCIS w/Invasive Cancer guideline		
2 mm		No ink on tumor		
Pure DCIS	DCIS with micro-invasion*	Invasive Cancer with DCIS**	Invasive Cancer	
*Defined as: DCIS w/ invasive focus <1mm				
Non-invasive	Non-invasive/ Minor invasive	Invasive Minor DCIS	Invasive	

NCCN NCCN NCCN Network<sup>®</sup>

# ive NCCN Guidelines Version 1.2021 Invasive Breast Cancer

# MARGIN STATUS RECOMMENDATIONS AFTER BREAST-CONSERVING SURGERY FOR INVASIVE CANCERS AND DCIS

# Invasive Breast Cancer

- For invasive breast cancers that have a component of DCIS, regardless of the extent of DCIS, the negative margin definition of "no ink on tumor" should be based on the invasive margin guideline. In this setting, "no ink on tumor" is recommended for either DCIS or invasive cancer cells, primarily because the natural history, treatment, and outcomes of these lesions are more similar to invasive cancer than DCIS. For specifically challenging cases, clinical judgment and discussion with the patient should precede routine re-excision.
- These margin recommendations cannot be applied directly to patients undergoing APBI,<sup>1</sup> where data regarding local recurrence are more limited. Furthermore, individualized clinical judgment should be utilized on a case-by-case basis, using postoperative mammography to identify residual calcifications and clinical-pathologic factors such as quantitative extent of disease near margin, presence of extensive intraductal component (EIC),<sup>3</sup> young age, or multiple close margins to assist in identifying patients who may have an increased risk of IBTR and therefore may be selected to benefit from re-excision.
- For patients with invasive breast cancer after BCS, with microscopically focally positive margins (in the absence of an EIC),<sup>3</sup> the use of a higher radiation boost dose to the tumor bed may be considered, since generally a boost to the tumor bed is recommended for patients at higher risk of recurrence. See BINV-I.

	No ink on tumor	2-mm margin	No margin necessary
Invasive breast cancer	X		
Invasive breast cancer + DCIS	X		
Invasive breast cancer + extensive DCIS	X		
Pure DCIS		X	
DCIS with microinvasion		X	
Pure LCIS* at surgical margin			X
Atypia at surgical margin			X

\*For pleomorphic LCIS, the optimal width of margins is not known.


<sup>1</sup> Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-


conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014 May 10;32(14):1507-1515.


<sup>3</sup> EIC is defined as an infiltrating ductal cancer where >25% of the tumor volume is DCIS and DCIS extends beyond the invasive cancer into surrounding normal breast parenchyma.


© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the	BINV-F
express written permission of NCCN <sup>®</sup> . To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.	2 OF 2


# BINV-2: Modifications to Local Regional Management














Characteristic, %	No RT	+ RT	<i>p</i> Value
Local control at 10 yrs actuarial n (%)	43 (9.8)	5(0.9)	.00008
Recurrence, n (%)			
Regional	13 (2.3)	3 (0.5)	.014
<ul> <li>Distant</li> </ul>	8 (1.9)	15 (3.6)	.07
Contralateral breast cancer	7 (1.2)	11 (2.2)	.20
New (nonbreast) cancer	49 (10.2)	40 (8.7)	.41
Deaths, n	89	81	69
10-yr actuarial rate, %	80.4	81.0	.68
10-yr metastasis-free survival, % (95% CI)	98.1 (96.7-99.6)	96.4 (94.5-98.4)	.28
Cause of death, n (%)			
<ul> <li>Cancer</li> </ul>	35 (39)	29 (37)	
Median follow-up: 7.3 yrs		Kunkler et. al. SABC	Dec 2020 . Abstr GS2-03


Characteristic, %	No RT	+ RT	<i>p</i> Value
Local control at 10 yrs actuarial n (%)	43 (9.8)	5(0.9)	.00008
Recurrence, n (%)			
<ul> <li>Regional</li> </ul>	13 (2.3)	3 (0.5)	.014
<ul> <li>Distant</li> </ul>	8 (1.9)	15 (3.6)	.07
<ul> <li>Contralateral breast cancer</li> </ul>	7 (1.2)	11 (2.2)	.20
New (nonbreast) cancer	49 (10.2)	40 (8.7)	.41
Deaths, n	89	81	<u> </u>
10-yr actuarial rate, %	80.4	81.0	.68
10-yr metastasis-free survival, % (95% Cl)	98.1 (96.7-99.6)	96.4 (94.5-98.4)	.28
Cause of death, n (%)			
Cancer	35 (39)	29 (37)	


Characteristic, %	No RT	+ RT	<i>p</i> Value
Local control at 10 yrs actuarial n (%)	43 (9.8)	5(0.9)	.00008
Recurrence, n (%) Regional	13 (2.3)	3 (0.5)	.014
Distant	8 (1.9)	15 (3.6)	.07
<ul><li>Contralateral breast cancer</li><li>New (nonbreast) cancer</li></ul>	7 (1.2) 49 (10.2)	11 (2.2) 40 (8.7)	.20 .41
Deaths, n ■ 10-yr actuarial rate, %	89 80.4	81 81.0	.68
10-yr metastasis-free survival, % (95% Cl)	98.1 (96.7-99.6)	96.4 (94.5-98.4)	.28
Cause of death, n (%)			
Cancer	35 (39)	29 (37)	

Characteristic, %	No RT	+ RT	<i>p</i> Value
Local control at 10 yrs actuarial n (%)	43 (9.8)	5(0.9)	.00008
Recurrence, n (%)		ar futur	;e
Regional	13 (2.3)	dod in near 104	.014
Distant	8 (1.9) bo EXE	andeu 15 (3.6)	.07
Contralateral breast cancer	tion may be on	11 (2.2)	.20
New (nonbreast) cancer	observation (10.2)	40 (8.7)	.41
Deaths, n criteria	89	81	
• 10-y patient select	80.4	81.0	.68
Recurrence, n (%)  Regional  Distant  Contralateral breast cancer  New (nonbreast) cancer  Deaths, n  10-y patient selection criteria for  10-yr metastasis-free survival, % (95% Cl)	98.1 (96.7-99.6)	96.4 (94.5-98.4)	.28
Cause of death, n (%)			
Cancer	35 (39)	29 (37)	

# BINV-2: 1-3+ Nodes


- Recommendation to 'Strongly consider regional nodal RT with WBRT' based on 2 phase III trials, MA-20 and EORTC that have demonstrate improved distant metastatic event free survival when RT is delivered to regional nodes
- Regional nodes defined as supra/infraclavicular, internal mammary, and undissected axilla
- The algorithm doesn't address lower risk patients with 1-3+ nodes





# ACOSOG Z0011 10 yr. Outcomes

- Despite criticisms of this trial:
  - Major deviations in the protocol: +SC Field: >20%; High Tangents:>50%; >10% did not get any WBRT
  - Not powered to show statistically significant differences; incomplete accrual
- Nodal relapses very rare (<2%) & LR relapses similarly low (<7%) @ 10 yrs
- Findings strongly suggest in this Z0011 population:
  - Irrespective of axillary adjuvant therapy (RT to axilla /completion ALND/no tx) axillary rec are rare
  - This population does not warrant more aggressive axillary treatment
  - ER negative dx (in and of itself) should not be an indication for more aggressive axillary tx



# BINV-I: Principles of Radiation Therapy

Nationa Comprehensive NCCN Cancer Network<sup>®</sup>

NCCN Guidelines Version 5.2020 **Invasive Breast Cancer** 

# PRINCIPLES OF RADIATION THERAPY

- Optimizing Delivery of Individual Therapy It is important to individualize RT planning and delivery.
- CT-based treatment planning is encouraged to delineate target volumes and adjacent organs at risk.
- Radiation to the breast/chest wall and nodal regions is generally delivered with photons ± electrons.
- · Greater target dose homogeneity and sparing of normal tissues can be accomplished using compensators such as wedges, forward planning using segments, and intensity-modulated RT (IMRT).
- Respiratory control techniques including deep inspiration breath-hold and prone positioning may be used to try to further reduce dose to adjacent heart and lung and adjacent normal tissue.
- Boost treatment in the setting of breast conservation can be delivered using enface electrons, photons, or brachytherapy. Chest wall scar boost when indicated is typically treated with electrons or photons.
- Verification of daily setup consistency is done with weekly imaging. When using certain techniques (ie, prone breast), more frequent imaging may be appropriate. Routine use of daily imaging is not recommended.

# Whole Breast Radiation

- Target definition is the breast tissue in entirety.
- RT dosing:
- > The whole breast should receive a dose of 45-50.4 Gy in 25-28 fractions or 40-42.5 Gy in 15-16 fractions (hypofractionation is preferred).
- A boost to the tumor bed is recommended in patients at higher risk for
- recurrence. Typical boost doses are 10-16 Gy in 4-8 fractions.
- All dose schedules are given 5 days per week.
- Chest Wall Radiation (including breast reconstruction)
- The target includes the ipsilateral chest wall, mastectomy scar, and drain sites when indicated.
- Depending on whether or not the patient has had breast reconstruction, several techniques using photons and/or electrons
- are appropriate. CT-based treatment planning is encouraged in order to identify lung and heart volumes and minimize exposure of these organs.
- > Special consideration should be given to the use of bolus material to
- ensure that the skin dose is adequate.
- RT dosing:
- Dose is 45-50.4 Gy in 25-28 fractions to the chest wall ± scar boost, at 1.8-2 Gy per fraction, to a total dose of approximately 60 Gy.
- All dose schedules are given 5 days per week.

- Regional Nodal Radiation Target delineation is best achieved by the use of CT-based treatment planning.
  - For the paraclavicular and axillary nodes, prescription depth varies based on the patient anatomy. • For internal mammary node identification, the internal mammary artery
  - and vein can be used as a surrogate for the nodal location (as the nodes themselves are not usually visible on planning imaging). Based on the post-mastectomy radiation randomized studies and recent trials, RT of the internal mammary nodal chain to include the first 3 intercostal spaces should be strongly considered when delivering regional nodal irradiation. When treating the internal mammary nodes, dose-volume histograms (DVHs) should be used to evaluate dose constraints, dose to normal tissues (ie, heart, lung), and planned target volumes (PTVs).
  - RT dosina: Dose is 45-50.4 Gy in 25-28 fractions to the regional nodal fields.
  - All dose schedules are given 5 days per week.

Accelerated Partial Breast Irradiation (APBI) • Studies of APBI suggest that rates of local control in selected low-risk patients with early-stage breast cancer may be comparable to those treated with standard WBRT. However, compared to standard WBRT, several studies document an inferior cosmetic outcome with APBI. Followup is limited and studies are ongoing.

- Patients are encouraged to participate in clinical trials.
- The NCCN Panel accepts the updated 2016 version of the ASTRO APBI guideline, which now defines patients "suitable" for APBI to be one of the following:
  - ◊ 1) ≥50 years with invasive ductal carcinoma measuring ≤2 cm (T1) disease) with negative margin widths of ≥2 mm, no LVI, ERpositive, and BRCA negative; or
  - ◊ 2) low/intermediate nuclear grade, screening-detected DCIS measuring size ≤2.5 cm with negative margin widths of ≥3 mm.
- RT dosing:
- A course of 34 Gy in 10 fractions delivered twice per day with brachytherapy of 38.5 Gy in 10 fractions delivered twice per day with external beam photon therapy is typically prescribed to the tumor bed. ◊ Other fractionation schemes are currently under investigation.

# Preoperative Systemic Therapy


 In patients treated with preoperative systemic therapy, adjuvant RT is based on the maximal disease stage (ie, clinical stage, pathologic stage, tumor characteristics) at diagnosis (before preoperative systemic therapy) and pathology results after preoperative systemic therapy.


Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®. BINV-I

NCCN National Comprehensive Cancer Network <sup>®</sup>	NCCN Guidelines Version 1.2021 Invasive Breast Cancer	
<ul> <li>CT-based treatment  </li> <li>Radiation to the brea</li> <li>Improved homogene forward planning usi</li> <li>Additional technique try to further reduce</li> <li>Verification of treatm imaging may be appression of the second When treating the int tissues (ie, heart, lun</li> </ul>	Individual Therapy idualize RT planning and delivery. planning should be routinely utilized to delineate target volumes and adjacent organs at risk. test/chest wall and nodal regions is generally delivered with single energy or mixed energy photons ± electrons. tity of the target dose and sparing of normal tissues can be accomplished using compensators such as wedges, ing segments, and intensity-modulated RT (IMRT). the such as respiratory control (deep inspiration breath-hold), prone positioning, cardiac blocks may also be used to dose to heart, lung, and adjacent normal tissue. Then t setup consistency is done with weekly imaging. When using certain techniques (ie, prone breast), more frequent ropriate. Standard utilization of daily imaging is not recommended. ternal mammary nodes, dose-volume histograms (DVHs) should be used to evaluate dose constraints, dose to normal teg), and planning target volumes (PTVs).	
		BINV-I 1 OF 3
	ncer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without th most recent and complete version of the NCCN Guidelines, go online to NCCN.org.	express written

# Dose Volume Histogram





Nationa Comprehensive NCCN Cancer Network<sup>®</sup>

NCCN Guidelines Version 5.2020 **Invasive Breast Cancer** 

# PRINCIPLES OF RADIATION THERAPY

# Optimizing Delivery of Individual Therapy • It is important to individualize RT planning and delivery.

- CT-based treatment planning is encouraged to delineate target volumes and adjacent organs at risk.
- Radiation to the breast/chest wall and nodal regions is generally
- delivered with photons ± electrons.
- · Greater target dose homogeneity and sparing of normal tissues can be accomplished using compensators such as wedges, forward planning using segments, and intensity-modulated RT (IMRT).
- Respiratory control techniques including deep inspiration breath-hold and prone positioning may be used to try to further reduce dose to adjacent heart and lung and adjacent normal tissue.
- Boost treatment in the setting of breast conservation can be delivered using enface electrons, photons, or brachytherapy. Chest wall scar boost when indicated is typically treated with electrons or photons. Verification of daily setup consistency is done with weekly imaging.
- When using certain techniques (ie, prone breast), more frequent imaging may be appropriate. Routine use of daily imaging is not recommended.

# Whole Breast Radiation

- Target definition is the breast tissue in entirety.
- RT dosing:
- > The whole breast should receive a dose of 45-50.4 Gy in 25-28 fractions or 40-42.5 Gy in 15-16 fractions (hypofractionation is preferred).
- A boost to the tumor bed is recommended in patients at higher risk for
- recurrence. Typical boost doses are 10-16 Gy in 4-8 fractions.
- All dose schedules are given 5 days per week.
- Chest Wall Radiation (including breast reconstruction)
- The target includes the ipsilateral chest wall, mastectomy scar, and drain sites when indicated.
- Depending on whether or not the patient has had breast reconstruction, several techniques using photons and/or electrons are appropriate.
- CT-based treatment planning is encouraged in order to identify lung and heart volumes and minimize exposure of these organs.
- > Special consideration should be given to the use of bolus material to
- ensure that the skin dose is adequate.

RT dosing:

- Dose is 45-50.4 Gy in 25-28 fractions to the chest wall ± scar boost, at 1.8-2 Gy per fraction, to a total dose of approximately 60 Gy.
- All dose schedules are given 5 days per week.

- Regional Nodal Radiation Target delineation is best achieved by the use of CT-based treatment planning.
  - For the paraclavicular and axillary nodes, prescription depth varies based on the patient anatomy. • For internal mammary node identification, the internal mammary artery
  - and vein can be used as a surrogate for the nodal location (as the nodes themselves are not usually visible on planning imaging). Based on the post-mastectomy radiation randomized studies and recent trials, RT of the internal mammary nodal chain to include the first 3 intercostal spaces should be strongly considered when delivering regional nodal irradiation. When treating the internal mammary nodes, dose-volume histograms (DVHs) should be used to evaluate dose constraints, dose to normal tissues (ie, heart, lung), and planned target volumes (PTVs).
  - RT dosina: Dose is 45–50.4 Gy in 25–28 fractions to the regional nodal fields.
  - All dose schedules are given 5 days per week.

Accelerated Partial Breast Irradiation (APBI) • Studies of APBI suggest that rates of local control in selected low-risk patients with early-stage breast cancer may be comparable to those treated with standard WBRT. However, compared to standard WBRT, several studies document an inferior cosmetic outcome with APBI. Followup is limited and studies are ongoing.

- Patients are encouraged to participate in clinical trials.
- The NCCN Panel accepts the updated 2016 version of the ASTRO APBI guideline, which now defines patients "suitable" for APBI to be one of the following:
  - ◊ 1) ≥50 years with invasive ductal carcinoma measuring ≤2 cm (T1) disease) with negative margin widths of ≥2 mm, no LVI, ERpositive, and BRCA negative; or
  - ◊ 2) low/intermediate nuclear grade, screening-detected DCIS measuring size ≤2.5 cm with negative margin widths of ≥3 mm.
- RT dosing:
- A course of 34 Gy in 10 fractions delivered twice per day with brachytherapy of 38.5 Gy in 10 fractions delivered twice per day with external beam photon therapy is typically prescribed to the tumor bed. ◊ Other fractionation schemes are currently under investigation.

# Preoperative Systemic Therapy


 In patients treated with preoperative systemic therapy, adjuvant RT is based on the maximal disease stage (ie, clinical stage, pathologic stage, tumor characteristics) at diagnosis (before preoperative systemic therapy) and pathology results after preoperative systemic therapy.


Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®. BINV-I


# ASTRO hWBRT Consensus 2011

Factor	2011 Guideline	2018 Guideline
Age	>50 years	Any
Stage	T1 or T2, N0	Any, provided only WBRT
Chemotherapy	No	Yes
Dose homogeneity	+/- 7% of the central axis	Volume >105% should be minimized
	Smith B, Int J Radiat Bio Phy 2011	Smith B, PRO, 2018
Almost all patient receiving WBRT alone (without regional nodal radiation) are eligible for moderately hWBRT		





# FAST-Forward Trial: 5 yr Follow-up



# FAST-Forward Trial: 5 yr. Outcomes

40 Gy in 15 fractions (n=1361)	27 Gy in five fractions (n=1367)	26 Gy in five fractions (n=1368)
31 (2·3%)	27 (2.0%)	21 (1.5%)
23 (1.7%)	22 (1.6%)	17 (1·2%)
6 (0.4%)	3 (0.2%)	4 (0·3%)
2 (0·1%)	2 (0.1%)	0
13 (1.0%)	11 (0.8%)	10 (0.7%)
59 (4·3%)	69 (5.0%)	76 (5.5%)
	15 fractions (n=1361)         31 (2·3%)         23 (1·7%)         6 (0·4%)         2 (0·1%)         13 (1·0%)	15 fractions (n=1361)five fractions (n=1367) $31 (2.3\%)$ $27 (2.0\%)$ $23 (1.7\%)$ $22 (1.6\%)$ $6 (0.4\%)$ $3 (0.2\%)$ $2 (0.1\%)$ $2 (0.1\%)$ $13 (1.0\%)$ $11 (0.8\%)$

- Local relapse: Non-inferiority bt 3 arms
- No detectable dose response bt 26 Gy and 27 Gy arms
- Patient & clinician-assessed normal tissue effects:
  - 26 Gy/5.2 Gy fx = 40 Gy/15
  - 26 Gy/5.2 Gy fx better than 27 Gy/5.4 Gy
  - 26Gy less mod/severe toxicity

Brunt AM, et al Lancet April 2020

	Network*
l	Nhole Breast Radiation
	Target definition is the breast tissue in entirety.
	RT dosing:
	The whole breast should receive a hypofractionated dose of 40–42.5 Gy in 15–16 fractions; in selected cases 45–50.4 Gy in 25–28 fractions may be considered.
	A boost to the tumor bed is recommended in patients at higher risk for recurrence. Typical boost doses are 10–16 Gy in 4–8 fractions.
	Lumpectomv cavitv boost can be delivered using enface electrons. photons. or brachvtherapv.
•	For patients who require a more limited number of treatment visits for WBRT delivery, ultra-hypofractionated WBRT of 28.5 Gy delivered as 5 (once-a-week) fractions, may be considered in selected patients aged ≥50 years following BCS with pTis/T1/T2/N0 tumors. However, late
	toxicity effects beyond 10 years are not currently defined.1
	The optimal fractionation for the delivery of a boost is not known for this regimen.
	→ 3-D planning to minimize inhomogeneity and exposure to heart and lung is essential when using this regimen.
	Brunt AM, Haviland JS, Sydenham M, et al. Ten-year results of FAST: A randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 2020;38(28):3261-3272.

Nationa Comprehensive NCCN Cancer Network<sup>®</sup>

NCCN Guidelines Version 5.2020 **Invasive Breast Cancer** 

# PRINCIPLES OF RADIATION THERAPY

- Optimizing Delivery of Individual Therapy It is important to individualize RT planning and delivery.
- CT-based treatment planning is encouraged to delineate target volumes and adjacent organs at risk.
- Radiation to the breast/chest wall and nodal regions is generally delivered with photons ± electrons.
- · Greater target dose homogeneity and sparing of normal tissues can be accomplished using compensators such as wedges, forward planning using segments, and intensity-modulated RT (IMRT).
- Respiratory control techniques including deep inspiration breath-hold and prone positioning may be used to try to further reduce dose to adjacent heart and lung and adjacent normal tissue.
- Boost treatment in the setting of breast conservation can be delivered using enface electrons, photons, or brachytherapy. Chest wall scar boost when indicated is typically treated with electrons or photons.
- Verification of daily setup consistency is done with weekly imaging. When using certain techniques (ie, prone breast), more frequent imaging may be appropriate. Routine use of daily imaging is not recommended.

- Whole Breast Radiation Target definition is the breast tissue in entirety.
- RT dosing:
- > The whole breast should receive a dose of 45-50.4 Gy in 25-28 fractions or 40-42.5 Gy in 15-16 fractions (hypofractionation is preferred).
- A boost to the tumor bed is recommended in patients at higher risk for recurrence. Typical boost doses are 10-16 Gy in 4-8 fractions.
- All dose schedules are given 5 days per week.
- Chest Wall Radiation (including breast reconstruction)
- The target includes the ipsilateral chest wall, mastectomy scar, and drain sites when indicated.
- Depending on whether or not the patient has had breast reconstruction, several techniques using photons and/or electrons are appropriate.
- CT-based treatment planning is encouraged in order to identify lung and heart volumes and minimize exposure of these organs.
- > Special consideration should be given to the use of bolus material to ensure that the skin dose is adequate.

- RT dosing:
- Dose is 45-50.4 Gy in 25-28 fractions to the chest wall ± scar boost, at 1.8-2 Gy per fraction, to a total dose of approximately 60 Gy.
- All dose schedules are given 5 days per week.

- Regional Nodal Radiation Target delineation is best achieved by the use of CT-based treatment planning.
  - For the paraclavicular and axillary nodes, prescription depth varies based on the patient anatomy. • For internal mammary node identification, the internal mammary artery
  - and vein can be used as a surrogate for the nodal location (as the nodes themselves are not usually visible on planning imaging). Based on the post-mastectomy radiation randomized studies and recent trials, RT of the internal mammary nodal chain to include the first 3 intercostal spaces should be strongly considered when delivering regional nodal irradiation. When treating the internal mammary nodes, dose-volume histograms (DVHs) should be used to evaluate dose constraints, dose to normal tissues (ie, heart, lung), and planned target volumes (PTVs).
  - RT dosina: Dose is 45–50.4 Gy in 25–28 fractions to the regional nodal fields. All dose schedules are given 5 days per week.

Accelerated Partial Breast Irradiation (APBI) • Studies of APBI suggest that rates of local control in selected low-risk patients with early-stage breast cancer may be comparable to those treated with standard WBRT. However, compared to standard WBRT, several studies document an inferior cosmetic outcome with APBI. Followup is limited and studies are ongoing.

- Patients are encouraged to participate in clinical trials.
- The NCCN Panel accepts the updated 2016 version of the ASTRO APBI guideline, which now defines patients "suitable" for APBI to be one of the following:
  - ◊ 1) ≥50 years with invasive ductal carcinoma measuring ≤2 cm (T1) disease) with negative margin widths of ≥2 mm, no LVI, ERpositive, and BRCA negative; or
  - ◊ 2) low/intermediate nuclear grade, screening-detected DCIS measuring size ≤2.5 cm with negative margin widths of ≥3 mm.
- RT dosing:
- A course of 34 Gy in 10 fractions delivered twice per day with brachytherapy of 38.5 Gy in 10 fractions delivered twice per day with external beam photon therapy is typically prescribed to the tumor bed. ◊ Other fractionation schemes are currently under investigation.

# Preoperative Systemic Therapy

 In patients treated with preoperative systemic therapy, adjuvant RT is based on the maximal disease stage (ie, clinical stage, pathologic stage, tumor characteristics) at diagnosis (before preoperative systemic therapy) and pathology results after preoperative systemic therapy.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®. BINV-I

NCCN National Comprehensive Cancer Network* NCCN Guidelines Version 1.2021 Invasive Breast Cancer	
PRINCIPLES OF RADIATION THERAPY	
<ul> <li>Chest Wall Radiation (including breast reconstruction)</li> <li>The target includes the ipsilateral chest wall, mastectomy scar, and drain sites when indicated.</li> <li>Depending on whether or not the patient has had breast reconstruction, several techniques using photons and/or electrons are appropriate.</li> <li>Special consideration should be given to the use of bolus material to ensure that the skin dose is adequate, particularly in the case of inflammatory breast cancer.</li> <li>RT dosing: <ul> <li>Dose is 45–50.4 Gy in 25–28 fractions to the chest wall ± scar boost, at 1.8–2 Gy per fraction, to a total dose of approximately 60–66 Gy.</li> <li>Chest wall scar boost may be delivered with or without bolus using electrons or photons.</li> </ul> </li> </ul>	
	BINV-I 2 OF 3
© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express w permission of NCCN <sup>®</sup> . To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.	ritten

Nationa Comprehensive NCCN Cancer Network<sup>®</sup>

NCCN Guidelines Version 5.2020 **Invasive Breast Cancer** 

# PRINCIPLES OF RADIATION THERAPY

- Optimizing Delivery of Individual Therapy It is important to individualize RT planning and delivery.
- CT-based treatment planning is encouraged to delineate target volumes and adjacent organs at risk.
- Radiation to the breast/chest wall and nodal regions is generally delivered with photons ± electrons.
- · Greater target dose homogeneity and sparing of normal tissues can be accomplished using compensators such as wedges, forward planning using segments, and intensity-modulated RT (IMRT).
- Respiratory control techniques including deep inspiration breath-hold and prone positioning may be used to try to further reduce dose to adjacent heart and lung and adjacent normal tissue.
- Boost treatment in the setting of breast conservation can be delivered using enface electrons, photons, or brachytherapy. Chest wall scar boost when indicated is typically treated with electrons or photons.
- Verification of daily setup consistency is done with weekly imaging. When using certain techniques (ie, prone breast), more frequent imaging may be appropriate. Routine use of daily imaging is not recommended.

- Whole Breast Radiation Target definition is the breast tissue in entirety.
- RT dosing:
- > The whole breast should receive a dose of 45-50.4 Gy in 25-28 fractions or 40-42.5 Gy in 15-16 fractions (hypofractionation is preferred).
- A boost to the tumor bed is recommended in patients at higher risk for
- recurrence. Typical boost doses are 10-16 Gy in 4-8 fractions.
- All dose schedules are given 5 days per week.
- Chest Wall Radiation (including breast reconstruction)
- The target includes the ipsilateral chest wall, mastectomy scar, and drain sites when indicated.
- Depending on whether or not the patient has had breast reconstruction, several techniques using photons and/or electrons are appropriate.
- CT-based treatment planning is encouraged in order to identify lung and heart volumes and minimize exposure of these organs.
- > Special consideration should be given to the use of bolus material to
- ensure that the skin dose is adequate.

RT dosing:

- Dose is 45-50.4 Gy in 25-28 fractions to the chest wall ± scar boost, at 1.8-2 Gy per fraction, to a total dose of approximately 60 Gy.
- All dose schedules are given 5 days per week.

- Regional Nodal Radiation Target delineation is best achieved by the use of CT-based treatment planning.
- > For the paraclavicular and axillary nodes, prescription depth varies based on the patient anatomy. • For internal mammary node identification, the internal mammary artery
- and vein can be used as a surrogate for the nodal location (as the nodes themselves are not usually visible on planning imaging). Based on the post-mastectomy radiation randomized studies and recent trials, RT of the internal mammary nodal chain to include the first 3 intercostal spaces should be strongly considered when delivering regional nodal irradiation. When treating the internal mammary nodes, dose-volume histograms (DVHs) should be used to evaluate dose constraints, dose to normal tissues (ie, heart, lung), and planned target volumes (PTVs).
- RT dosing: Dose is 45-50.4 Gy in 25-28 fractions to the regional nodal fields. All dose schedules are given 5 days per week.

Accelerated Partial Breast Irradiation (APBI) • Studies of APBI suggest that rates of local control in selected low-risk patients with early-stage breast cancer may be comparable to those treated with standard WBRT. However, compared to standard WBRT, several studies document an inferior cosmetic outcome with APBI. Followup is limited and studies are ongoing.

- Patients are encouraged to participate in clinical trials.
- The NCCN Panel accepts the updated 2016 version of the ASTRO APBI guideline, which now defines patients "suitable" for APBI to be one of the following:
  - ◊ 1) ≥50 years with invasive ductal carcinoma measuring ≤2 cm (T1) disease) with negative margin widths of ≥2 mm, no LVI, ERpositive, and BRCA negative; or
  - ◊ 2) low/intermediate nuclear grade, screening-detected DCIS measuring size ≤2.5 cm with negative margin widths of ≥3 mm.
- RT dosing:
- A course of 34 Gy in 10 fractions delivered twice per day with brachytherapy of 38.5 Gy in 10 fractions delivered twice per day with external beam photon therapy is typically prescribed to the tumor bed. ◊ Other fractionation schemes are currently under investigation.


# Preoperative Systemic Therapy

 In patients treated with preoperative systemic therapy, adjuvant RT is based on the maximal disease stage (ie, clinical stage, pathologic stage, tumor characteristics) at diagnosis (before preoperative systemic therapy) and pathology results after preoperative systemic therapy.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®. BINV-I

# Multiple Breast Atlases Available to Contour Nodes at Risk



Comprenensive	NCCN Guidelines Version 1.2021 Invasive Breast Cancer	
<ul> <li>Regional nodes should be con</li> <li>RT dosing:</li> <li>Dose is 45–50.4 Gy in 25–28</li> </ul>	y nodes, prescription depth varies based on the patient anatomy. ntoured when considering regional nodal RT. Refer to breast atlases for contou fractions to the regional nodal fields. Can be delivered to grossly involved or enlarged lymph nodes (ie, internal mar ed.	
Radiother Oncol 2015;114(1):3-10.	RO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. ntouring guidelines for the axillary lymph nodes for the delivery of radiation therapy in breast cancer: Evaluation of the Biol Phys 2015;93(2):257-265.	BINV-I 2 OF 3
© 2021 National Comprehensive Cancer	r Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in a ost recent and complete version of the NCCN Guidelines, go online to NCCN.org.	any form without the express written

Nationa Comprehensive NCCN Cancer Network<sup>®</sup>

NCCN Guidelines Version 5.2020 **Invasive Breast Cancer** 

# PRINCIPLES OF RADIATION THERAPY

- Optimizing Delivery of Individual Therapy It is important to individualize RT planning and delivery.
- CT-based treatment planning is encouraged to delineate target volumes and adjacent organs at risk.
- Radiation to the breast/chest wall and nodal regions is generally delivered with photons ± electrons.
- · Greater target dose homogeneity and sparing of normal tissues can be accomplished using compensators such as wedges, forward planning using segments, and intensity-modulated RT (IMRT).
- Respiratory control techniques including deep inspiration breath-hold and prone positioning may be used to try to further reduce dose to adjacent heart and lung and adjacent normal tissue.
- Boost treatment in the setting of breast conservation can be delivered using enface electrons, photons, or brachytherapy. Chest wall scar boost when indicated is typically treated with electrons or photons.
- Verification of daily setup consistency is done with weekly imaging. When using certain techniques (ie, prone breast), more frequent imaging may be appropriate. Routine use of daily imaging is not recommended.

- Whole Breast Radiation Target definition is the breast tissue in entirety.
- RT dosing:
- > The whole breast should receive a dose of 45-50.4 Gy in 25-28 fractions or 40-42.5 Gy in 15-16 fractions (hypofractionation is preferred).
- A boost to the tumor bed is recommended in patients at higher risk for
- recurrence. Typical boost doses are 10-16 Gy in 4-8 fractions.
- All dose schedules are given 5 days per week.
- Chest Wall Radiation (including breast reconstruction)
- The target includes the ipsilateral chest wall, mastectomy scar, and drain sites when indicated.
- Depending on whether or not the patient has had breast reconstruction, several techniques using photons and/or electrons are appropriate.
- CT-based treatment planning is encouraged in order to identify lung and heart volumes and minimize exposure of these organs.
- > Special consideration should be given to the use of bolus material to
- ensure that the skin dose is adequate.

RT dosing:

- Dose is 45-50.4 Gy in 25-28 fractions to the chest wall ± scar boost, at 1.8-2 Gy per fraction, to a total dose of approximately 60 Gy.
- All dose schedules are given 5 days per week.

- Regional Nodal Radiation Target delineation is best achieved by the use of CT-based treatment planning.
  - For the paraclavicular and axillary nodes, prescription depth varies based on the patient anatomy. • For internal mammary node identification, the internal mammary artery
  - and vein can be used as a surrogate for the nodal location (as the nodes themselves are not usually visible on planning imaging). Based on the post-mastectomy radiation randomized studies and recent trials, RT of the internal mammary nodal chain to include the first 3 intercostal spaces should be strongly considered when delivering regional nodal irradiation. When treating the internal mammary nodes, dose-volume histograms (DVHs) should be used to evaluate dose constraints, dose to normal tissues (ie, heart, lung), and planned target volumes (PTVs).
  - RT dosina: Dose is 45-50.4 Gy in 25-28 fractions to the regional nodal fields.
  - All dose schedules are given 5 days per week.

# Accelerated Partial Breast Irradiation (APBI)

- Studies of APBI suggest that rates of local control in selected low-risk patients with early-stage breast cancer may be comparable to those treated with standard WBRT. However, compared to standard WBRT, several studies document an inferior cosmetic outcome with APBI. Followup is limited and studies are ongoing.
- Patients are encouraged to participate in clinical trials.
- The NCCN Panel accepts the updated 2016 version of the ASTRO APBI guideline, which now defines patients "suitable" for APBI to be one of the following:
  - ◊ 1) ≥50 years with invasive ductal carcinoma measuring ≤2 cm (T1) disease) with negative margin widths of ≥2 mm, no LVI, ERpositive, and BRCA negative; or
  - ◊ 2) low/intermediate nuclear grade, screening-detected DCIS measuring size ≤2.5 cm with negative margin widths of ≥3 mm.
- RT dosing:
- A course of 34 Gy in 10 fractions delivered twice per day with brachytherapy of 38.5 Gy in 10 fractions delivered twice per day with external beam photon therapy is typically prescribed to the tumor bed. ◊ Other fractionation schemes are currently under investigation.

# Preoperative Systemic Therapy


 In patients treated with preoperative systemic therapy, adjuvant RT is based on the maximal disease stage (ie, clinical stage, pathologic stage, tumor characteristics) at diagnosis (before preoperative systemic therapy) and pathology results after preoperative systemic therapy.


Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.


© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®. BINV-I


# ASTRO APBI Consensus "Suitable" 2009 vs. 2016 Criteria

Factor	2009 Guideline	2016 Guideline
Age	>60 years	>50
Margins	Negative by at least 2mm	Negative by at least 2mm
Stage	T1 only	T1 or Tis
Histology	IDC	IDC
LVI	No	No
DCIS	Not Allowed	If following criteria are met: • Screen detected • GI or GII • Size <2.5 cm • Margins >3mm
	Smith B,Int J Radiat Bio Phy 2011	Correa PRO, 2016









RAPID	NSABP B-39
8-year cumulative results: APBI: strictly external beam 3.0% APBI vs. 2.8% WBRT non-inferior Worse cosmetic outcomes with EBRT	<ul> <li>10-year cumulative outcomes IBTR:</li> <li>APBI: external beam single-entry catheter multi-entry catheter techniques</li> <li>4.6% APBI vs. 3.9% cf WBRT Not non-inferior</li> <li>Not worse cosmetic outcomes w/EBRT APBI</li> </ul>
Whelan T, 2019 Lancet	Vicini F, 2019 Lancet

NCCN NCCN NCCN Network<sup>®</sup>

# Invasive Breast Cancer

# **PRINCIPLES OF RADIATION THERAPY**

Accelerated Partial Breast Irradiation (APBI)

• Studies of APBI suggest that rates of local control in selected low-risk patients with early-stage breast cancer may be comparable to those treated with standard WBRT. However, compared to standard WBRT, several studies document an inferior cosmetic outcome with external beam delivery methods of APBI. Follow-up is limited and studies are ongoing.

Patients are encouraged to participate in clinical trials.

The NCCN Panel accepts the updated 2016 version of the ASTRO APBI guideline consensus statement, which now defines patients age ≥50 years to be considered "suitable" for APBI if:

◊ Invasive ductal carcinoma measuring ≤2 cm (pT1 disease) with negative margin widths of ≥2 mm, no LVI, ER-positive, and BRCA negative; or

◊ Low/intermediate nuclear grade, screening-detected DCIS measuring size ≤2.5 cm with negative margin widths of ≥3 mm.

# RT dosing

Regimen	Method	Reference
30 Gy/5 fractions QOD (preferred)	External beam RT (EBRT) <sup>a</sup>	Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015;51:451-463. Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast
<sup>a</sup> The protocol mandated IMRT.		irradiation for early breast cancer: Long-term results of the randomized phase III APBI-IMRT-Florence Trial. J Clin Oncol 2020;38:4175-4183.
40 Gy/15 fractions	EBRT	Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017;390:1048-1060.
34 Gy/10 fractions BID	Balloon/ Interstitial	Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 2019;394:2155-2164.
38.5 Gy/10 fractions BID	EBRT	Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 2019;394:2165-2172.

© 2021 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN®. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.

National Comprehensive NCCN Cancer Network®

# • Who We Are

An alliance of leading cancer centers devoted to patient care, research, and education

# • Our Mission

To improve and facilitate quality, effective, efficient, and accessible cancer care so patients can live better lives

# Our Vision

To define and advance highquality, high-value, patientcentered cancer care globally

# **NCCN Member Institutions**

